Viravaxx

Papers

Borochova K, Niespodziana K, Focke-Tejkl M, Hofer G, Keller W, Valenta R. Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response (2021), Scientific Reports volume 11, 3551; https://www.nature.com/articles/s41598-021-82893-y

 

Kratzer B, Trapin D, Ettel P, Körmöczi U, Rottal A, Tuppy F, Feichter M, Gattinger P, Borochova K, Dorofeeva Y, Tulaeva I, Weber M, Grabmeier-Pfisterhammer K, Tauber P, Gerdov M, Mühl B, Perkmann T, Fae I, Wennda S, Führer H, Henning R, Valenta R, Pickl W. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations (2020). Allergy, 2020;00:1-15; https://doi.org/10.1111/all.14647.

 

Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B, Mühl B, Perkmann T, Trapin D, Trella M, Ettel P, Tulaeva I, Pickl W, Valenta R. Antibodies in serum of convalescent patients following mild COVID‐19 do not always prevent virus‐receptor binding (2020). Allergy, 2020;00:1-6; https://doi.org/10.1111/all.14523.

 

Tulaeva I, Cornelius C, Zieglmayer P, Zieglmayer R, Schmutz R, Lemell P, Weber M, Focke-Tejkl M, Karaulov A, Henning R, Valenta R (2020). Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32EBioMedicine 59: 102953; https://doi.org/10.1016/j.ebiom.2020.102953

 

Niespodziana K, Borochova K, Pazderova P … Zaikov S, Zidarn M, Valenta R (2020). Toward personalization of asthma treatment according to trigger factors. Clin. Rev. Allergy Immun. 145 (6): 1529-1534; https://doi.org/10.1016/j.jaci.2020.02.001

 

Pazderova P, Waltl EE, Niederberger-Leppin V, Flicker S, Valenta R, Niespodziana K.(2020). ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions. Vaccines, 8(2): 315; https://doi.org/10.3390/vaccines8020315

 

Sam Narean J, Glanville N, Nunn CM, Niespodziana K, Valenta R, Johnston SL, McLean GR (2019). Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity. Vaccine. 37(21): 2805-2813; https://doi.org/10.1016/j.vaccine.2019.04.018

 

Niespodziana K, Stenberg-Hammar K, Megremis S, Cabauatan CR, Napora-Wijata, K, Vacal PC, Gallerano D, Lupinek C, Ebner D, Schlederer T, Harwanegg C, Söderhäll C, Van Hage M, Hedlin G, Papadopoulos NG, Valenta R (2018). PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze. Nature Communications 9: 2328; https://dx.doi.org/10.1038%2Fs41467-018-04591-0 

 

Gerlich WH and Glebe D (2016). Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B VaccineEBioMedicine 11: 5-6; doi: https://dx.doi.org/10.1016%2Fj.ebiom.2016.07.032

 

Cornelius C, Schöneweis K, Georgi F et al. (2016). Immunotherapy with the preS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B infection. EBioMedicine 11: 58-67.

 

Niespodziana K, Cabauatan CR, Jackson DJ, Gallerano D et al. (2015). Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. EBioMedicine  2(1): 64–70.

 

McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL. (2012). Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 95(3):193-201.

 

Edlmayr J, Niespodziana K, Popow-Kraupp T, Krzyzanek V, Focke-Tejkl M, Blaas D, Grote M, Valenta R. (2011). Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisationEur Respir J.  37(1):44-52.